Literature DB >> 25157176

Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation.

Severa Bunda1, Pardeep Heir2, Tharan Srikumar3, Jonathan D Cook2, Kelly Burrell4, Yoshihito Kano1, Jeffrey E Lee2, Gelareh Zadeh4, Brian Raught3, Michael Ohh5.   

Abstract

Mutations in Ras GTPase and various other components of the Ras signaling pathways are among the most common genetic alterations in human cancers and also have been identified in several familial developmental syndromes. Over the past few decades it has become clear that the activity or the oncogenic potential of Ras is dependent on the nonreceptor tyrosine kinase Src to promote the Ras/Raf/MAPK pathway essential for proliferation, differentiation, and survival of eukaryotic cells. However, no direct relationship between Ras and Src has been established. We show here that Src binds to and phosphorylates GTP-, but not GDP-, loaded Ras on a conserved Y32 residue within the switch I region in vitro and that in vivo, Ras-Y32 phosphorylation markedly reduces the binding to effector Raf and concomitantly increases binding to GTPase-activating proteins and the rate of GTP hydrolysis. These results suggest that, in the context of predetermined crystallographic structures, Ras-Y32 serves as an Src-dependent keystone regulatory residue that modulates Ras GTPase activity and ensures unidirectionality to the Ras GTPase cycle.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25157176      PMCID: PMC4246987          DOI: 10.1073/pnas.1406559111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Toc34 is a preprotein receptor regulated by GTP and phosphorylation.

Authors:  N Sveshnikova; J Soll; E Schleiff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  Tyrosine phosphorylation of G protein alpha subunits by pp60c-src.

Authors:  W P Hausdorff; J A Pitcher; D K Luttrell; M E Linder; H Kurose; S J Parsons; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  Molecular switch in signal transduction: reaction paths of the conformational changes in ras p21.

Authors:  J Ma; M Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 4.  How Ras-related proteins talk to their effectors.

Authors:  A Wittinghofer; N Nassar
Journal:  Trends Biochem Sci       Date:  1996-12       Impact factor: 13.807

5.  Activation kinetics of RAF protein in the ternary complex of RAF, RAS-GTP, and kinase on the plasma membrane of living cells: single-molecule imaging analysis.

Authors:  Kayo Hibino; Tatsuo Shibata; Toshio Yanagida; Yasushi Sako
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

6.  Guanosine triphosphatase stimulation of oncogenic Ras mutants.

Authors:  M R Ahmadian; T Zor; D Vogt; W Kabsch; Z Selinger; A Wittinghofer; K Scheffzek
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 7.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

8.  Differential Regulation of RasGAPs in Cancer.

Authors:  Thomas Grewal; Meryem Koese; Francesc Tebar; Carlos Enrich
Journal:  Genes Cancer       Date:  2011-03

9.  Oncogenic Ras/Src cooperativity in pancreatic neoplasia.

Authors:  D J Shields; E A Murphy; J S Desgrosellier; A Mielgo; S K M Lau; L A Barnes; J Lesperance; M Huang; C Schmedt; D Tarin; A M Lowy; D A Cheresh
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

10.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

View more
  36 in total

Review 1.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

2.  Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Authors:  Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

Review 3.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

4.  Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding.

Authors:  Pamela Y Ting; Christian W Johnson; Cong Fang; Xiaoqing Cao; Thomas G Graeber; Carla Mattos; John Colicelli
Journal:  FASEB J       Date:  2015-05-21       Impact factor: 5.191

Review 5.  RAS isoforms and mutations in cancer at a glance.

Authors:  G Aaron Hobbs; Channing J Der; Kent L Rossman
Journal:  J Cell Sci       Date:  2016-03-16       Impact factor: 5.285

6.  Conformational and Dynamical Effects of Tyr32 Phosphorylation in K-Ras: Molecular Dynamics Simulation and Markov State Models Analysis.

Authors:  Mohammed Khaled; Alemayehu Gorfe; Abdallah Sayyed-Ahmad
Journal:  J Phys Chem B       Date:  2019-08-30       Impact factor: 2.991

7.  PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Authors:  Kristen S Hill; Evan R Roberts; Xue Wang; Ellen Marin; Taeeun D Park; Sorany Son; Yuan Ren; Bin Fang; Sean Yoder; Sungjune Kim; Lixin Wan; Amod A Sarnaik; John M Koomen; Jane L Messina; Jamie K Teer; Youngchul Kim; Jie Wu; Charles E Chalfant; Minjung Kim
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

8.  Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Authors:  Chelsea Jenkins; Samuel B Luty; Julia E Maxson; Christopher A Eide; Melissa L Abel; Corinne Togiai; Eneida R Nemecek; Daniel Bottomly; Shannon K McWeeney; Beth Wilmot; Marc Loriaux; Bill H Chang; Jeffrey W Tyner
Journal:  Sci Signal       Date:  2018-07-17       Impact factor: 8.192

Review 9.  Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.

Authors:  Mitchell I Parker; Anna S Nikonova; Danlin Sun; Erica A Golemis
Journal:  Cell Signal       Date:  2019-12-09       Impact factor: 4.315

Review 10.  Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Authors:  Imran Khan; J Matthew Rhett; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-10-31       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.